RecruitingEarly Phase 1NCT07000682
The Clinical Study on the Treatment of SSc With UTAA91 Injection.
Studying Systemic sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Intervention
- UTAA91 injection(biological)
- Enrollment
- 24 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2040
Study locations (1)
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07000682 on ClinicalTrials.govOther trials for Systemic sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07402226Systemic Sclerosis DIet for GastrointESTinal SymptomsUniversity of Michigan
- RECRUITINGEARLY PHASE1NCT07355972Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSCUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGNANCT07360808Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic SclerosisCytori Therapeutics
- RECRUITINGNCT07228429Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography ImagesYale University
- RECRUITINGPHASE1NCT07167537A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune DiseasesBeijing GoBroad Hospital
- RECRUITINGNCT06865118Home-Based Clinical Management of Cardiac Complications in Systemic SclerosisOslo University Hospital
- RECRUITINGNANCT06675344The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of LifeRobyn T. Domsic, MD, MPH
- RECRUITINGEARLY PHASE1NCT06775912Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune DiseasesNanjing Bioheng Biotech Co., Ltd.